First-in-human first-in-class phase I trial of murlentamab, an anti-Mullerian-hormone receptor II (AMHRII) monoclonal antibody acting through tumor-associated macrophage (TAM) engagement, as single agent and in combination with carboplatin (C) and pa

Geraldine O' Sullivan Coyne, MD, discusses the Phase I Trial fo Murlentamab.<br /><br />Background:<br />Membranous expression of AMHRII is found in ~70% of gynecological tumors. Murlentamab (M) binds with high a... Author: Annual-Meeting Added: 06/07/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts